Sorafenib Outcomes Unaffected by Age
ISTANBUL—Age does not affect clinical outcomes in sorafenib-treated patients with advanced renal cell carcinoma (RCC), researchers announced here at the 31st congress of the European Society for Medical Oncology.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.